FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2108380963> ?p ?o ?g. }

• W2108380963 endingPage "449" @default.
• W2108380963 startingPage "439" @default.
• W2108380963 abstract "No AccessJournal of UrologyReview article1 Aug 2006Continuing Controversy Over Monitoring Men With Localized Prostate Cancer: A Systematic Review of Programs in the Prostate Specific Antigen Era Richard M. Martin, David Gunnell, Freddie Hamdy, David Neal, Athene Lane, and Jenny Donovan Richard M. MartinRichard M. Martin Department of Social Medicine, University of Bristol, Bristol More articles by this author , David GunnellDavid Gunnell Department of Social Medicine, University of Bristol, Bristol More articles by this author , Freddie HamdyFreddie Hamdy Division of Clinical Sciences (South), University of Sheffield, Sheffield More articles by this author , David NealDavid Neal Oncology Centre, University of Cambridge, Cambridge, United Kingdom Financial interest and/or other relationship with GlaxoSmithKline and AstraZeneca. More articles by this author , Athene LaneAthene Lane Department of Social Medicine, University of Bristol, Bristol More articles by this author , and Jenny DonovanJenny Donovan Department of Social Medicine, University of Bristol, Bristol More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2006.03.030AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: There is continuing controversy over the most appropriate treatment for screen detected and clinically localized prostate cancer, and increasing interest in monitoring such men initially with radical treatment targeted at cancers showing signs of progressive potential but while they are still curable. Current evidence on monitoring protocols and biomarkers used to predict disease progression was systematically reviewed. Materials and Methods: The MEDLINE and Excerpta Medica (EMBASE) bibliographic databases were searched from 1988 to October 2004, supplemented by manual searches of reference lists, focusing on studies reporting monitoring of men with localized prostate cancer. Results: A total of 48 potentially eligible articles were found but only 5 studies, in which there was a total of 451 participants, restricted entry criteria to men with clinically localized (T1-T2) prostate cancer. Monitoring protocols varied with little consensus, although the majority used prostate specific antigen and digital rectal examination, while some added re-biopsy to assess progression. Actuarial probabilities of freedom from disease progression at 4 to 5 years of followup were 67% to 72%. However, up to 50% of men abandoned monitoring within 2 years, largely because of anxiety related to increasing prostate specific antigen rather than objective evidence of disease progression. There was no robust evidence to support prostate specific antigen doubling times or velocity to identify men in whom disease may progress. Studies were characterized by small sample size, short-term followup, observer bias and uncertain validity around variable definitions of progression. Conclusions: Current evidence suggests that some form of monitoring would be a suitable treatment option in men with localized prostate cancer but there is little consensus over what markers should be used in such a program or how progression should be properly defined. The search for a method that safely identifies men with prostate cancer who could avoid radical intervention must continue. References 1 : Cancer burden in the year 2000. The global picture. Eur J Cancer2001; 37: 4. Google Scholar 2 : Localised prostatic cancer: management and detection issues. Lancet1994; 343: 1263. Google Scholar 3 : Progress toward identifying aggressive prostate cancer. N Engl J Med2004; 351: 180. Google Scholar 4 : Screening for prostate cancer. Lancet2003; 361: 1122. Google Scholar 5 : Evaluation of changes in prostate specific antigen in clinically localized prostate cancer managed without initial therapy. J Urol1998; 159: 1243. Link, Google Scholar 6 : Delayed therapy with curative intent in a contemporary prostate cancer watchful-waiting cohort. BJU Int2004; 93: 510. Google Scholar 7 : Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. J Clin Oncol2003; 21: 4001. Google Scholar 8 : Predictors of treatment after initial surveillance in men with prostate cancer: results from CaPSURE. J Urol2003; 170: 2279. Link, Google Scholar 9 : Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy. J Urol2001; 166: 1702. Link, Google Scholar 10 : Prostate specific antigen velocity as a measure of the natural history of prostate cancer: defining a ‘rapid riser’ subset. Br J Urol1998; 81: 100. Google Scholar 11 : Watchful waiting and factors predictive of secondary treatment of localized prostate cancer. J Urol2004; 171: 1111. Link, Google Scholar 12 : Variations in PSA doubling time in patients with prostate cancer on “watchful waiting”: value of short-term PSADT determinations. Urology2004; 64: 323. Google Scholar 13 : An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol2004; 171: 1520. Link, Google Scholar 14 : Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer?. J Urol2003; 170: 2274. Link, Google Scholar 15 : Clinical outcome of patients with stage T1a prostate cancer. J Chin Med Assoc2003; 66: 236. Google Scholar 16 : Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol2002; 167: 1664. Link, Google Scholar 17 : Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer. Urology2002; 59: 652. Google Scholar 18 : Correlation of initial PSA level and biopsy features with PSA-doubling time in early stage prostate cancers in Japanese men. Eur Urol2002; 41: 47. Google Scholar 19 : Molecular prediction of progression in patients with conservatively managed prostate cancer. Urology2001; 58: 762. Google Scholar 20 : The role of volume-weighted mean nuclear volume in predicting tumour biology and clinical behaviour in patients with prostate cancer undergoing watchful waiting. BJU Int2001; 88: 909. Google Scholar 21 : Deferred treatment of localized prostate cancer in the elderly: the impact of the age and stage at the time of diagnosis on the treatment decision. BJU Int2000; 85: 699. Google Scholar 22 : Watchful waiting or watchful progression? Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma. Cancer1998; 82: 342. Google Scholar 23 : Expectant management as an option for men with stage T1c prostate cancer: a preliminary study. World J Urol1997; 15: 364. Google Scholar 24 : Tumour markers in patients on deferred treatment: prostate specific antigen doubling times. Cancer Surv1995; 23: 157. Google Scholar 25 : Serial prostate specific antigen measurements and progression in untreated confined (stages T0 to 3NxM0, grades 1 to 3) carcinoma of the prostate. J Urol1995; 154: 1403. Link, Google Scholar 26 : Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease. J Urol2001; 166: 1688. Link, Google Scholar 27 : Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol2002; 167: 1231. Link, Google Scholar 28 : Wide variation of prostate-specific antigen doubling time of untreated, clinically localized, low-to-intermediate grade, prostate carcinoma. BJU Int2004; 94: 295. Google Scholar 29 : The role of serial free/total prostate-specific antigen ratios in a watchful observation protocol for men with localized prostate cancer. BJU Int2002; 89: 703. Google Scholar 30 : The dynamics of prostate specific antigen during watchful waiting of prostate carcinoma: a study of 94 Japanese men. Cancer2002; 94: 1692. Google Scholar 31 : Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA1998; 280: 975. Google Scholar 32 : Clinical significance of repeat sextant biopsies in prostate cancer patients. Urology, suppl.1997; 49: 113. Google Scholar 33 : Relationship between changes in prostate-specific antigen and prognosis of prostate cancer. Urology1993; 42: 383. Google Scholar 34 : Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients. J Urol1989; 141: 1070. Google Scholar 35 : Natural history of changes in prostate specific antigen in early stage prostate cancer. J Urol1994; 152: 1743. Abstract, Google Scholar 36 : Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. New Engl J Med2004; 351: 125. Google Scholar 37 : Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. Urology1997; 49: 379. Google Scholar 38 : Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE. J Urol2003; 170: 1804. Link, Google Scholar 39 : Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer1998; 78: 940. Google Scholar 40 : Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. Clin Cancer Res2000; 6: 1882. Google Scholar 41 : p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting. J Urol2000; 164: 716. Link, Google Scholar 42 : Tumor cell proliferation and survival in patients with prostate cancer followed expectantly. J Urol1998; 159: 1609. Link, Google Scholar 43 : DNA ploidy and survival of patients with clinically localized prostate cancer treated without intent to cure. Prostate1998; 36: 244. Google Scholar 44 : Genetic alterations in incidentally diagnosed, transitional zone prostate cancer: a 7-year followup. J Urol1997; 158: 1568. Link, Google Scholar 45 : c-erbB-2 oncoprotein: a potential biomarker of advanced prostate cancer. Prostate1997; 30: 195. Google Scholar © 2006 by American Urological AssociationFiguresReferencesRelatedDetailsCited byLoo R, Shapiro C, Tamaddon K, Chien G, Rhee E and Jacobsen S (2018) The Continuum of Prostate Cancer Care: An Integrated Population Based Model of Health Care DeliveryUrology Practice, VOL. 2, NO. 2, (78-84), Online publication date: 1-Mar-2015.Martin R and Donovan J (2018) Editorial CommentJournal of Urology, VOL. 180, NO. 4, (1340-1341), Online publication date: 1-Oct-2008.Griffin C, Yu X, Loeb S, Desireddi V, Han M, Graif T and Catalona W (2018) Pathological Features After Radical Prostatectomy in Potential Candidates for Active MonitoringJournal of Urology, VOL. 178, NO. 3, (860-863), Online publication date: 1-Sep-2007.Venkitaraman R, Norman A, Woode-Amissah R, Fisher C, Dearnaley D, Horwich A, Huddart R, Khoo V, Thompson A and Parker C (2018) Predictors of Histological Disease Progression in Untreated, Localized Prostate CancerJournal of Urology, VOL. 178, NO. 3, (833-837), Online publication date: 1-Sep-2007. Volume 176Issue 2August 2006Page: 439-449 Advertisement Copyright & Permissions© 2006 by American Urological AssociationKeywordsdisease progressionprognosisprostatic neoplasmsprostateprostate-specific antigenMetricsAuthor Information Richard M. Martin Department of Social Medicine, University of Bristol, Bristol More articles by this author David Gunnell Department of Social Medicine, University of Bristol, Bristol More articles by this author Freddie Hamdy Division of Clinical Sciences (South), University of Sheffield, Sheffield More articles by this author David Neal Oncology Centre, University of Cambridge, Cambridge, United Kingdom Financial interest and/or other relationship with GlaxoSmithKline and AstraZeneca. More articles by this author Athene Lane Department of Social Medicine, University of Bristol, Bristol More articles by this author Jenny Donovan Department of Social Medicine, University of Bristol, Bristol More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2108380963 created "2016-06-24" @default.
• W2108380963 creator A5012694886 @default.
• W2108380963 creator A5027462458 @default.
• W2108380963 creator A5049636639 @default.
• W2108380963 creator A5059408838 @default.
• W2108380963 creator A5065571043 @default.
• W2108380963 creator A5090783984 @default.
• W2108380963 date "2006-08-01" @default.
• W2108380963 modified "2023-10-18" @default.
• W2108380963 title "Continuing Controversy Over Monitoring Men With Localized Prostate Cancer: A Systematic Review of Programs in the Prostate Specific Antigen Era" @default.
• W2108380963 cites W1508120635 @default.
• W2108380963 cites W1509856083 @default.
• W2108380963 cites W1533951690 @default.
• W2108380963 cites W1555363895 @default.
• W2108380963 cites W1602530656 @default.
• W2108380963 cites W1969875009 @default.
• W2108380963 cites W1977407960 @default.
• W2108380963 cites W1977689836 @default.
• W2108380963 cites W1982902142 @default.
• W2108380963 cites W1984657334 @default.
• W2108380963 cites W1999683372 @default.
• W2108380963 cites W2002482549 @default.
• W2108380963 cites W2006378078 @default.
• W2108380963 cites W2010958938 @default.
• W2108380963 cites W2011463851 @default.
• W2108380963 cites W2016042280 @default.
• W2108380963 cites W2017284566 @default.
• W2108380963 cites W2026648444 @default.
• W2108380963 cites W2033747629 @default.
• W2108380963 cites W2035828101 @default.
• W2108380963 cites W2045482904 @default.
• W2108380963 cites W2046599355 @default.
• W2108380963 cites W2050782913 @default.
• W2108380963 cites W2065909337 @default.
• W2108380963 cites W2070040127 @default.
• W2108380963 cites W2070428637 @default.
• W2108380963 cites W2075459864 @default.
• W2108380963 cites W2081037663 @default.
• W2108380963 cites W2095900336 @default.
• W2108380963 cites W2112689533 @default.
• W2108380963 cites W2113137744 @default.
• W2108380963 cites W2122739032 @default.
• W2108380963 cites W2124050465 @default.
• W2108380963 cites W2130502504 @default.
• W2108380963 cites W2133342754 @default.
• W2108380963 cites W2135988380 @default.
• W2108380963 cites W2141703378 @default.
• W2108380963 cites W2148081587 @default.
• W2108380963 cites W2156776019 @default.
• W2108380963 cites W2411388718 @default.
• W2108380963 cites W4298032180 @default.
• W2108380963 cites W78998479 @default.
• W2108380963 doi "https://doi.org/10.1016/j.juro.2006.03.030" @default.
• W2108380963 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2875171" @default.
• W2108380963 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16813862" @default.
• W2108380963 hasPublicationYear "2006" @default.
• W2108380963 type Work @default.
• W2108380963 sameAs 2108380963 @default.
• W2108380963 citedByCount "45" @default.
• W2108380963 countsByYear W21083809632012 @default.
• W2108380963 countsByYear W21083809632013 @default.
• W2108380963 countsByYear W21083809632014 @default.
• W2108380963 countsByYear W21083809632015 @default.
• W2108380963 countsByYear W21083809632017 @default.
• W2108380963 countsByYear W21083809632018 @default.
• W2108380963 crossrefType "journal-article" @default.
• W2108380963 hasAuthorship W2108380963A5012694886 @default.
• W2108380963 hasAuthorship W2108380963A5027462458 @default.
• W2108380963 hasAuthorship W2108380963A5049636639 @default.
• W2108380963 hasAuthorship W2108380963A5059408838 @default.
• W2108380963 hasAuthorship W2108380963A5065571043 @default.
• W2108380963 hasAuthorship W2108380963A5090783984 @default.
• W2108380963 hasBestOaLocation W21083809632 @default.
• W2108380963 hasConcept C121608353 @default.
• W2108380963 hasConcept C126322002 @default.
• W2108380963 hasConcept C143998085 @default.
• W2108380963 hasConcept C2776235491 @default.
• W2108380963 hasConcept C2780192828 @default.
• W2108380963 hasConcept C2781114028 @default.
• W2108380963 hasConcept C2781406297 @default.
• W2108380963 hasConcept C29456083 @default.
• W2108380963 hasConcept C71924100 @default.
• W2108380963 hasConceptScore W2108380963C121608353 @default.
• W2108380963 hasConceptScore W2108380963C126322002 @default.
• W2108380963 hasConceptScore W2108380963C143998085 @default.
• W2108380963 hasConceptScore W2108380963C2776235491 @default.
• W2108380963 hasConceptScore W2108380963C2780192828 @default.
• W2108380963 hasConceptScore W2108380963C2781114028 @default.
• W2108380963 hasConceptScore W2108380963C2781406297 @default.
• W2108380963 hasConceptScore W2108380963C29456083 @default.
• W2108380963 hasConceptScore W2108380963C71924100 @default.
• W2108380963 hasIssue "2" @default.
• W2108380963 hasLocation W21083809631 @default.
• W2108380963 hasLocation W21083809632 @default.
• W2108380963 hasLocation W21083809633 @default.
• W2108380963 hasLocation W21083809634 @default.
• W2108380963 hasOpenAccess W2108380963 @default.

• next